ArticleCadernos de saude publica2026
[The precautionary principle in preventive actions: considerations on an absence].
Article in Cadernos de saude publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The precautionary principle (PP) consists of measures to be taken to avoid harm under serious damage or catastrophe to the environment or human health and scientific uncertainty about its causes and/or incidence. However, PP has not been used to prevent severe iatrogenic harm from actions derived from primary (P1) or secondary (P2) prevention actions in medicine or health systems. This essay synthesizes a proposal for this use, defends its adequacy, and offers four comprehensive, interconnected, and synergistic hypotheses as to why it is yet to occur: (a) such use is very anti-intuitive due to the teleological similarity between PP and prevention and their contextual differences; (b) the future moral expansion of medicine has generated a preventive supremacy that unrestrictedly expands tolerance to P1/P2 iatrogenesis; (c) some of these iatrogenic diseases are anomalies (in Thomas Kuhn's sense) with complex identification and measurement, making it difficult to accept and value them; (d) the following ongoing naturalization of preventive iatrogenesis makes it unthinkable to consider PP for its management in serious cases of doubt, leaving it outside the horizon of preventive medicine and paradoxically making it more necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.